Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- MSD Cautions against Syncope, Fall after Gardasil Vaccination
February 15, 2012
- Major Pharmacy Chains to Boost Efforts to Raise GE Dispensing Rates Despite Dissatisfaction with Revised Premiums
February 15, 2012
- Altheos Initiates PIIa Trial for ATS907 in the US: Asahi Kasei Pharma
February 14, 2012
- Sawai Wins Patent Lawsuit on Ebastine
February 14, 2012
- Dispensing Pharmacies Set to Reopen in Disaster-Hit Areas
February 14, 2012
- Otsuka HD Director Kimura Anticipates Seroquel Patent Expiry to Impact Abilify
February 14, 2012
- AnGes MG to Seek Return of ¥75 Million Patent Remuneration from Board Member Morishita
February 14, 2012
- Otsuka HD Files Application for Antituberculosis Drug Delamanid in Europe
February 13, 2012
- April-December Pharmaceutical Sales Up 4.1% Driven by Abilify: Otsuka HD
February 13, 2012
- Altheos Begins PIIa Trial for ATS907 in US: Asahi Kasei Pharma
February 13, 2012
- AnGes MG Announces Positive Results from Exploratory Trial of CIN Vaccine
February 13, 2012
- Nippon Kayaku to Make Largest-ever Investment in Pharma R&D, with Shift to Biosimilars
February 13, 2012
- Nichi-Iko to Shift Back Priority to Its Own Generics from Transferred Long-Listed Products
February 13, 2012
- Takeda Sets Up Development Center at China Subsidiary to Boost Development in Asia
February 10, 2012
- Eisai to Transfer Shares and Equity of its Pharmaceutical Machinery Business Subsidiaries
February 10, 2012
- Nomura Report Recommends Otsuka HD, DSP, Eisai Shares
February 10, 2012
- Mr Takeuchi of Astellas Stresses Importance of IP Strategies in Tie-ups with Bioventures
February 10, 2012
- Teijin Aims for ¥400 Billion in Sales in Healthcare by FY2020
February 9, 2012
- Sales of Ethical Drugs Up 5.3% in December: Crecon Report
February 9, 2012
- Meiji Seika Pharma Begins PII Trial of Schizophrenia Drug Ziprasidone in Japan
February 9, 2012
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…